Ashland Inc. (ASH)
NYSE: ASH
· Real-Time Price · USD
48.78
0.89 (1.86%)
At close: Sep 26, 2025, 3:59 PM
48.79
0.02%
After-hours: Sep 26, 2025, 06:28 PM EDT
Ashland Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermediates And Solvents Revenue | 71M | 36M | 40M | 33M | 406M | 219M | 240M | 207M | 213M | 228M | 204M | 170M | 41M | 33M | 20M | 21M | 14M | 21M | 84M | 30M | 84M | 90M | 69M | 84M | 83M | 90M |
| Intermediates And Solvents Revenue Growth | +97.22% | -10.00% | +21.21% | -91.87% | +85.39% | -8.75% | +15.94% | -2.82% | -6.58% | +11.76% | +20.00% | +314.63% | +24.24% | +65.00% | -4.76% | +50.00% | -33.33% | -75.00% | +180.00% | -64.29% | -6.67% | +30.43% | -17.86% | +1.20% | -7.78% | n/a |
| Life Sciences Revenue | 388M | 195M | 222M | 200M | 288M | 152M | 161M | 143M | 187M | 194M | 182M | 156M | 58M | 60M | 60M | 51M | 60M | 58M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Life Sciences Revenue Growth | +98.97% | -12.16% | +11.00% | -30.56% | +89.47% | -5.59% | +12.59% | -23.53% | -3.61% | +6.59% | +16.67% | +168.97% | -3.33% | 0.00% | +17.65% | -15.00% | +3.45% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Personal Care And Household Revenue | 336M | 175M | 169M | 129M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 51M | 46M | 42M | 41M | 52M | 42M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Personal Care And Household Revenue Growth | +92.00% | +3.55% | +31.01% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +10.87% | +9.52% | +2.44% | -21.15% | +23.81% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Specialty Additives Revenue | 293M | 150M | 157M | 122M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 57M | 53M | 48M | 45M | 51M | 50M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Specialty Additives Revenue Growth | +95.33% | -4.46% | +28.69% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | +7.55% | +10.42% | +6.67% | -11.76% | +2.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 106M | 85M | 78M | 101M | 114M | 106M | 83M | 109M | 82M | 79M | 93M | 94M | 127M | 90M | 82M | 69M | 93M | 79M | 101M | 109M | 113M | 103M | 99M | 110M | 128M | 115M | 121M | 234M | 181M | 146M | 154M | 177M | 182M | 155M | 157M | 502M | 160M | 258M | 224M | 383M | 216M | 203M |
| Selling, General, and Administrative Revenue Growth | +24.71% | +8.97% | -22.77% | -11.40% | +7.55% | +27.71% | -23.85% | +32.93% | +3.80% | -15.05% | -1.06% | -25.98% | +41.11% | +9.76% | +18.84% | -25.81% | +17.72% | -21.78% | -7.34% | -3.54% | +9.71% | +4.04% | -10.00% | -14.06% | +11.30% | -4.96% | -48.29% | +29.28% | +23.97% | -5.19% | -12.99% | -2.75% | +17.42% | -1.27% | -68.73% | +213.75% | -37.98% | +15.18% | -41.51% | +77.31% | +6.40% | n/a |
| Research and Development Revenue | 13M | 14M | 13M | 13M | 15M | 14M | 12M | 14M | 12M | 12M | 13M | 15M | 14M | 13M | 13M | 13M | 15M | 14M | 15M | 16M | 14M | 18M | 16M | 15M | 17M | 17M | 17M | 21M | 21M | 21M | 21M | 22M | 20M | 24M | 23M | 26M | 22M | 25M | 25M | 36M | 24M | 25M |
| Research and Development Revenue Growth | -7.14% | +7.69% | 0.00% | -13.33% | +7.14% | +16.67% | -14.29% | +16.67% | 0.00% | -7.69% | -13.33% | +7.14% | +7.69% | 0.00% | 0.00% | -13.33% | +7.14% | -6.67% | -6.25% | +14.29% | -22.22% | +12.50% | +6.67% | -11.76% | 0.00% | 0.00% | -19.05% | 0.00% | 0.00% | 0.00% | -4.55% | +10.00% | -16.67% | +4.35% | -11.54% | +18.18% | -12.00% | 0.00% | -30.56% | +50.00% | -4.00% | n/a |